A single oral dose of methylene blue is able to increase the response of brain regions that control attention and short-term memory, according to University of Texas Health Science Center researchers.

Eisai has partnered with Geisinger to assess whether a machine-learning model can accurately identify people with cognitive impairment — which may suggest early signs of dementia. Machine learning is ...

While there is no cure for Alzheimer’s disease, nor have any disease-modifying therapies been approved yet, there are several medications available by prescription to treat disease symptoms that ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

The U.S. Food and Drug Administration (FDA) has approved BrainSee, Darmiyan’s software for predicting the likelihood that a person with mild cognitive impairment (MCI) will progress to Alzheimer’s ...

Researchers have found a connection between an infection with the parasite Toxoplasma gondii and neurodegenerative diseases such as Alzheimer’s. The study, “Toxoplasma Modulates Signature Pathways of ...

A biomarker blood test called AlzoSure Predict that can help to identify people with mild cognitive impairment who are likely progress to Alzheimer’s disease — years before symptoms are evident — has ...

The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease.

Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk by measuring levels of certain forms of the amyloid beta protein, a known ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Posit Science, which produces the BrainHQ app, is collaborating with the YMCA of San Francisco to establish a model community-based program for dementia prevention. Posit Science received a $465,000 ...

Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. “Cassava Sciences is a ...